Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410-a Modifier Gene Therapy-in Phase 1/2 ArMaDa Study for Geographic Atrophy
Stock Information for Ocugen, Inc.
Loading
Please wait while we load your information from QuoteMedia.